Plasma homocysteine and microvascular complications in type 1 diabetes

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 10, Issue 6, 2000, Pages 297-304

  Vaccaro, O ^a,c   Perna, A F ^b   Mancini, F P ^a   Iovine, C ^a   Cuomo, V ^a   Sacco, M ^a   Tufano, A ^a   Rivellese, A A ^a   Ingrosso, D ^b   Riccardi, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Policlin dell'Univ Studi F ^*  (Italy)

Author keywords

Folic acid; Homocysteine; Microalbuminuria; Retinopathy; Type 1 diabetes; Vitamin B12

Indexed keywords

CREATININE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); OXIDOREDUCTASE;

ADULT; ALBUMINURIA; ARTICLE; BLOOD; CASE CONTROL STUDY; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; FEMALE; GENETICS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLISM; POINT MUTATION;

ADULT; ALBUMINURIA; CASE-CONTROL STUDIES; CREATININE; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POINT MUTATION; VITAMIN B 12;

EID: 0034573061     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Stampfer MJ, Malinow RM, Willett WC, Newcomer LM, Upson B, Ullmann C, Tishlor PV, Hennekens CH (1992) A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 268: 877-881
2. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274: 1049-1057
3. Nygård O, Nordrehaug JE, Refsum H, Ueland M, Farstad M, Vollset SE (1997) Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337: 230-236
4. Welch GN, Loscalzo J (1998) Homocysteine and atherothrombosis. N Engl J Med 338: 1042-1050
5. Refsum H, Ueland P (1998) Recent data are not in conflict with homocysteine as a cardiovascular risk factor. Curr Opin Lipidol 9: 533-539
6. Mancini FP, Di Minno G (1996) Hyperhomocysteinemia and thrombosis: the search for a link. Nutr Metab Cardiovasc Dis 6: 168-177
7. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, Heistad DD (1996) Vascular dysfunction in monkeys with diet-induced hyperhomocysteinemia. J Clin Invest 98: 24-29
8. Dennis VW, Nurko S, Robinson K (1997) Hyperhomocysteinemia: detection, risk assessment and treatment. Curr Opin Nephrol Hypertens 6: 483-488
9. Feener EP, King GL (1997) Vascular dysfunction in diabetes mellitus. Lancet 350: (Suppl) 9-13
10. Lentz SR (1998) Mechanism of thrombosis in hyperhomocysteinemia. Curr Opinon Hematol 5: 343-349
11. Hultberg B, Agardh E, Andersson A, Brattstrom L, Isaksson A, Israelsson B, Agardh D (1991) Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus. Scand J Clin Invest 51: 277-282
12. Agardh CD, Agardh E, Andersson A, Hultberg B (1994) Lack of association between plasma homocysteine levels and microangiopathy in type 1 diabetes mellitus. Scand J Clin Invest 54: 637-641
13. Neugebauer S, Tsuneharu B, Kurokawa K, Watanabe T (1997) Defective homocysteine metabolism as a risk factor for diabetic retinopathy. Lancet 349: 473-474
14. Vaccaro O, Ingrosso D, Rivellese A, Greco G, Riccardi G (1997) Moderate hyperhomocysteinemia and retinopathy in insulin-dependent diabetes. Lancet 349: 1102-1103
15. Chico A, Perez A, Cordoba A, Arcelus R, Carreras G, de Leiva A, Gonzalez-Sastre F, Blanco-Vaca F (1998) Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? Diabetologia 41: 684-693
16. Hofmann MA, Kohl B, Zubach MS, Borcea V, Bierhaus A, Henkels M, Amiral J, Fiehn W, Ziegler R, Wahl P, Nawroth PP (1998) Hyperhomocysteinemia and endothelial dysfunction in IDDM. Diabetes Care 21: 841-848
17. Cronin CC, McPartlin JM, Barry DG, Barry Ferriss J, Scott JM, Weir DG (1998) Plasma homocysteine concentrations in patients with type 1 diabetes. Diabetes Care 21: 1843-1847
18. Kark JD, Selhub J, Bostom A, Adler B, Rosenberg JH (1999) Plasma homocysteine and all-cause mortality in diabetes. Lancet 353: 1936-1937
19. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen R (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10: 111-113
20. Rose GA, Blackburn H, Gillum RF, Prineas RJ (1982) Cardiovascular survey methods, 2nd ed. WHO, Geneva (Monogr Ser No 56)
21. -lie AK for the EURODIAB IDDM Complications Study Group (1995) Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM Complications Study. Diabetologia 38: 437-444
22. Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris LF, Klein R (1998) Diabetic retinopathy. Diabetes Care 43: 143-156
23. Ubbink JB, Vermaak WJH, Bissbort S (1991) Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 565: 441-446
24. Perna AF, Ingrosso D, De Santo NG, Galletti P, Zappia V (1995) Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Int 47: 247-253
25. American Diabetes Association (1997) Diabetic nephropathy. Position Statement. Diabetes Care 20: (Suppl 1) S24-S27
26. Fleiss JL (1981) Statistical methods for rates and proportions, 2nd ed. John Wiley & Sons Inc.
27. Wollesen F, Brattstrom L, Refsum H, Ueland PM, Berglund L, Berne C (1999) Plasma total homosysteine and cystein in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 55: 1028-1035
28. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH (1993) Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 270: 2693-2698
29. Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosemberg IH (1999) The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 340: 1449-1454
30. Evrovski J, Cole DE (1999) Clinical chemistry and molecular biology of homocysteine metabolism: an update. Clin Biochem 3: 189-201
31. Fioretto P, Steffes MW, Mauer M (1994) Glomerular structure in non proteinuric IDDM patients with various levels of albuminuria. Diabetes 43: 1358-1364
32. van Guldener C, Donker AJ, Jakobs C, Teerlink T, de Meer K (1998) No net renal extraction of homocysteine in fasting humans. Kidney Int 54: 166-169
33. D'Angelo A, Coppola A, Madonna P, Fermo I, Pagano A, Mazzola G, Galli L, Cerbone AM (2000) The role of vitamin B12 in fasting hyperhomocysteinemia and its interaction with the homozygous C677T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene. Tromb Haemostas 83: 563-570
34. Alcolado J (1998) Genetics of diabetic complications. Lancet 351: 230-231
35. Krolewski AS (1999) Genetics of diabetic nephropathy: evidence for major and minor gene effect. Kidney Int 55: 1582-1596
36. The Diabetes Control and Complications Trial Study Group (1993) The effect of intensive treatment of diabetes in the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med 329: 304-307
37. Klein R (1995) Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 18: 258-268
38. Dudman NPB (1999) An alternative view of homocysteine. Lancet 354: 2072-2074
39. Neugebauer S, Baba T, Watanabe T (1998) Methylenetetrahydrofolate reductase gene polymorfism as a risk factor for diabetic nephropathy in NIDDM patients. Lancet 352: 454
40. Bluther M, Bruntgens A, Schmidt S, Strjek K, Grzeszczak W, Ritz E (1999) Association of methylenetetrahydrofolate reductase gene polymorphism and diabetic nephropathy in type 2 diabetes? Nephrol Dial Transplant 14: 56-57
41. Smyth JS, Savage DA, Maxwell AP (1999) MTHFR gene polymorphism and diabetic nephropathy in type 1 diabetes. Lancet 353: 1156
42. Odawara M, Yamashita K (1999) A common mutation of the methylenetetrahydrofolate reductase gene as risk factor for diabetic nephropathy. Diabetologia 42: 631-632
43. Ellsworth DL, Manolio TA (1999) The emerging importance of genetics in epidemiology research. Issues in study design and gene mapping. Ann Epidemiol 9: 75-90